Higher doses of prescription psychostimulants, treatment duration positively linked to longer retention
Rapid induction to extended-release buprenorphine 300-mg injection feasible and well tolerated for those using fentanyl
Higher 90-day treatment retention rates seen with no higher risk for overdose
Implementation of opioid use disorder screening does not increase percentage of patients with new diagnosis
Receipt of physical therapy and chiropractic care was low overall and lower across racial, ethnic minorities
The nasal spray version of naloxone will be available at select retailers for $44.99 for a box of two doses
Yet, only 46 percent of those with addiction in their families say that person got treatment
Medications for OUD more likely for those with severe versus mild past-year OUD, receiving substance use treatment via telehealth
Integrated behavioral health services may help address patient needs with opioid use disorder, the authors say
Few offer other evidence-based treatments